Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term safety and efficacy study of VX-121 + tezacaftor + deutivacaftor in cystic fibrosis
MOH_2023-02-13_012349Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vanzacaftor, tezacaftor and deutivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2023-02-13_012349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-13_012349.